Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLEVIPREX vs ADALAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cleviprex (clevidipine) is a dihydropyridine L-type calcium channel blocker with high vascular selectivity. It inhibits calcium influx into vascular smooth muscle cells, causing arterial vasodilation and reduced peripheral vascular resistance.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
For the reduction of blood pressure when oral therapy is not feasible or desirable,For the management of perioperative hypertension
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Initiate intravenous infusion at 1-2 mg/kg/hr, titrate by 0.5-1 mg/kg/hr every 90 minutes up to maximum 32 mg/kg/hr. Maintenance dose: 4-6 mg/kg/hr. Route: IV. Frequency: continuous infusion.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
Terminal elimination half-life: 2.7 minutes (dihydropyridine ring reduction) and 15 minutes (ester hydrolysis); clinical context: rapid offset allows precise titration
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Rapidly metabolized by esterases in the blood and extravascular tissues to an inactive carboxylic acid metabolite (H152/81). Not primarily dependent on hepatic CYP450 enzymes.
Hepatic via CYP3A4; extensive first-pass metabolism; metabolites are inactive.
Renal: 63–73% as metabolites, fecal: 7–10%, unchanged drug in urine: <1%
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
87–97% bound to plasma proteins (primarily albumin)
92-98% bound to plasma proteins (albumin and alpha-1-acid glycoprotein)
0.32 L/kg (approx. 22 L for 70 kg); indicates limited extravascular distribution
0.8-1.2 L/kg. Clinical meaning: indicates extensive tissue distribution, consistent with high lipophilicity.
Intravenous: 100% (only route administered)
Oral immediate-release: 45-60% (due to first-pass metabolism); extended-release: 60-85% (due to slower release and reduced first-pass effect).
No dose adjustment required for renal impairment. Clevidipine is not removed by dialysis.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, use with caution and reduce initial dose by 50%.
Contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). Use with caution in moderate impairment (Child-Pugh B); consider lower initial doses and titrate slowly.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce by 75%.
Safety and efficacy not established in pediatric patients. No FDA-approved dosing recommendations.
0.25-0.5 mg/kg/dose orally every 6-8 hours; maximum 3 mg/kg/day. Extended-release not recommended.
No specific dose adjustment required. Elderly patients may be more sensitive to hypotensive effects; use lower initial doses and titrate cautiously.
Start at 10 mg orally twice daily; titrate slowly due to increased sensitivity and risk of hypotension.
None.
None
Use caution in patients with heart failure, as beta-blocker withdrawal may exacerbate angina; continue beta-blocker therapy.,Hypotension and reflex tachycardia may occur; monitor blood pressure and heart rate closely.,Can cause acute kidney injury or worsening of renal function in at-risk patients.,Lipid emulsion formulation; use caution in patients with severe hypertriglyceridemia or lipid metabolism disorders.,Contains soybean oil and egg lecithin; contraindicated in patients with allergies to soybeans or eggs.,Not recommended for use in pediatric patients due to lack of safety and efficacy data.
May cause hypotension, especially in patients on beta-blockers or with poor cardiac reserve,Risk of increased angina and/or myocardial infarction upon initiation or dose increase,Peripheral edema,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hepatic impairment,Exacerbation of angina on withdrawal
Hypersensitivity to clevidipine or any component of the formulation (including soybean oil or egg lecithin),Severe aortic stenosis (may reduce cardiac output and worsen symptoms),Patients with defective lipid metabolism (e.g., hyperlipoproteinemia, lipoid nephrosis, acute pancreatitis with hyperlipidemia)
Hypersensitivity to nifedipine,Cardiogenic shock,Significant aortic stenosis,Concurrent use with rifampin,Pregnancy (category C)
No specific food interactions; administer IV only. The lipid emulsion contains soybean oil and egg lecithin; contraindicated in patients with allergies to soy or eggs. No oral intake required.
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 and increase nifedipine serum concentrations, leading to enhanced hypotensive effects and risk of toxicity. Grapefruit interaction persists for 24 hours; separate consumption by at least 4 hours if unavoidable, but preferable to avoid entirely. Avoid alcohol which can increase hypotension. High-fat meals may reduce absorption of extended-release formulations; take consistently with or without food.
Cleviprex (clevidipine) is a calcium channel blocker. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at clinically relevant doses. However, maternal toxicity at high doses led to fetal effects (reduced fetal weight, delayed ossification). First trimester: limited data; risk cannot be excluded. Second and third trimesters: may cause fetal acidosis, hypotension, and bradycardia due to maternal hypotension. Use only if potential benefit justifies potential risk.
First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibition. Category C.
No data on presence in human milk or effects on breastfed infants. Clevidipine is highly protein-bound (>99%) and rapidly metabolized, suggesting minimal excretion into milk. However, caution is advised. M/P ratio: not determined.
Excreted in breast milk; M/P ratio ~0.85. Consider risks versus benefits; monitor infant for hypotension.
No specific dose adjustments studied in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) may affect clearance, but no data. Use lowest effective dose and shortest duration. Titrate to effect with caution, as pregnant patients may have increased sensitivity to hypotensive effects.
No standard dose adjustment; monitor clinical response and blood pressure; may require lower doses due to vasodilation effects.
CLEVIPREX (clevidipine) is an ultrashort-acting dihydropyridine calcium channel blocker for IV use in perioperative hypertension. Onset within 2-4 minutes, half-life ~1 minute. Titrate every 5-10 minutes; avoid in severe aortic stenosis, heart failure with reduced ejection fraction, and lipid disorders (formulated in lipid emulsion). Monitor for reflex tachycardia. Use aseptic technique; discard unused portion after 12 hours.
Adalat (nifedipine) is a dihydropyridine calcium channel blocker. Use immediate-release capsules only for hypertensive emergencies, not chronic treatment due to risk of reflex tachycardia and unpredictable hypotension. Extended-release formulations are preferred for stable angina and hypertension. Avoid grapefruit juice as it increases nifedipine levels via CYP3A4 inhibition. Monitor for peripheral edema, gingival hyperplasia, and constipation. Contraindicated in cardiogenic shock, severe aortic stenosis, and within 4 weeks of myocardial infarction.
This medication is given intravenously to rapidly lower blood pressure during surgery or in hospital settings.,You will be closely monitored for heart rate and blood pressure changes during infusion.,Report any symptoms like chest pain, shortness of breath, or irregular heartbeat immediately.,Do not stop or adjust the infusion on your own; it is controlled by healthcare staff.,Inform your doctor if you have any allergies to eggs, soybeans, or lipids.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit and grapefruit juice while taking this medication.,Report persistent swelling of ankles/feet, gum tenderness or bleeding, or severe dizziness.,Do not stop abruptly; taper under medical supervision to avoid rebound hypertension.,Take at the same time each day; if a dose is missed, skip it if near next dose.,May cause dizziness; avoid driving until you know how it affects you.,Increase fluid and fiber intake to prevent constipation.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLEVIPREX vs ADALAT, answered by our medical review team.
CLEVIPREX is a Calcium Channel Blocker that works by Cleviprex (clevidipine) is a dihydropyridine L-type calcium channel blocker with high vascular selectivity. It inhibits calcium influx into vascular smooth muscle cells, causing arterial vasodilation and reduced peripheral vascular resistance.. ADALAT is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLEVIPREX and ADALAT depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLEVIPREX is: Initiate intravenous infusion at 1-2 mg/kg/hr, titrate by 0.5-1 mg/kg/hr every 90 minutes up to maximum 32 mg/kg/hr. Maintenance dose: 4-6 mg/kg/hr. Route: IV. Frequency: continuous infusion.. The standard adult dose of ADALAT is: 10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLEVIPREX and ADALAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLEVIPREX is classified as Category C. Cleviprex (clevidipine) is a calcium channel blocker. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at clinical. ADALAT is classified as Category C. First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibiti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.